Marked response to both S-1 and pemetrexed in a patient with echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase-positive lung adenocarcinoma
| Autor: | Kazuto Nishio, Kazuhiko Nakagawa, Hiroyasu Kaneda, Masayuki Takeda, Junko Tanizaki, Isamu Okamoto, Kazuko Sakai |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Oncology
medicine.medical_specialty Crizotinib biology Oncogene business.industry medicine.drug_class Hematology General Medicine medicine.disease Echinoderm Microtubule-Associated Protein-Like 4 Thymidylate synthase respiratory tract diseases ALK inhibitor Pemetrexed hemic and lymphatic diseases Internal medicine medicine biology.protein Adenocarcinoma Anaplastic lymphoma kinase Radiology Nuclear Medicine and imaging business medicine.drug |
| Zdroj: | Acta Oncologica. 51:942-944 |
| ISSN: | 1651-226X 0284-186X |
| Popis: | Fusion between echinoderm microtubule-associated protein-like 4 (EML4) and anaplastic lymphoma kinase (ALK) genes has recently been identified in non-small cell lung cancer (nSCLC). The aLK inhibitor crizotinib has shown promising activity in patients whose tumors harbor this oncogene [1], but it has remained unclear whether such patients manifest similar sensitivity to cytotoxic chemotherapy. Two recent studies have suggested that ALK rearrangements may be a predictor of efficacy for the thymidylate synthase (TS)-targeted agent pemetrexed in terms of both response rate and progression-free survival in nSCLC [2,3]. S-1 also targets TS and has shown promising results in a phase III trial as a firstline treatment for patients with advanced nSCLC [4]. we now report a dramatic response to both S-1 and pemetrexed in a patient with EML4-ALKpositive nSCLC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|